← All countries · Africa
62%
MCV1
2025 · WHO/UNICEF estimate
78%
DTP3
2025 · WHO/UNICEF estimate
78%
HepB3
2025 · WHO/UNICEF estimate
79
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2016 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 76%2025 · WHO/UNICEF estimate | 75.5% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 84%2025 · WHO/UNICEF estimate | 83.5% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 78%2025 · WHO/UNICEF estimate | 78.3% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 80%2025 · WHO/UNICEF estimate | 79.8% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | —% · Administrative (country-reported) | — | too few points | no data |
| MCV1First dose of measles-containing vaccine | 62%2025 · WHO/UNICEF estimate | 62.2% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 53%2025 · WHO/UNICEF estimate | 52.8% | C · weak | |
| RCV1First dose of rubella-containing vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| HepB3Third dose of hepatitis B vaccine | 78%2025 · WHO/UNICEF estimate | 78.5% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 66.2%2024 · Administrative (country-reported) | 66.2% | too few points | D · poor |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 78%2025 · WHO/UNICEF estimate | 78.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 48%2017 · Administrative (country-reported) | 48% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | no data |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | 62%2025 · WHO/UNICEF estimate | 62.3% | B · good | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 60%2024 · WHO/UNICEF estimate | — | C · weak |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 792025 | 40.8per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02016 | 0per 1,000,000 total population | D · poor | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02016 | 0per 1,000,000 total population | D · poor | |
| Diphtheria all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Tetanus (total) all countries · vaccine evidence | 162025 | 8.3per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 52025 | 0.1per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 02022 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 62025 | 3.1per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 1,5682025 | 808.9per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (33 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | NACIDOS VIVOS |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | W10 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | W14 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 4 | M18 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | NACIDOS VIVOS |
| IPVIPV (Inactivated polio vaccine) | 1 | W14 | General/routine | NIÑOS SUPERVIVIENTES |
| MEASLESMeasles vaccine | 1 | M9 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| MEASLESMeasles vaccine | 2 | M18 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| OPVOPV (Oral polio vaccine) | 1 | B | General/routine | NIÑOS SUPERVIVIENTES |
| OPVOPV (Oral polio vaccine) | 2 | W6 | General/routine | NIÑOS SUPERVIVIENTES |
| OPVOPV (Oral polio vaccine) | 3 | W10 | General/routine | NIÑOS SUPERVIVIENTES |
| OPVOPV (Oral polio vaccine) | 4 | W14 | General/routine | NIÑOS SUPERVIVIENTES |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | General/routine | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Adults | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | General/routine | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Adults | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | General/routine | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Adults | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | General/routine | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Adults | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | General/routine | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| VITAMINAVitamin A supplements | 4 | M23 | General/routine | NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES |
| YFYF (Yellow fever) vaccine | 1 | M9 | General/routine | NIÑOS SUPERVIVIENTES |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.